About Sigilon
Sigilon is a company based in Cambridge (United States) founded in 2015 by Omid Veiseh was acquired by Lilly in June 2023. Sigilon has raised $103.8 million across 3 funding rounds from investors including Lilly, BlackRock and Flagship Pioneering. The company has 66 employees as of December 31, 2021. Sigilon operates in a competitive market with competitors including Neurocrine, Crinetics, Zucara Therapeutics, MBX Biosciences and Amolyt Pharma, among others.
- Headquarter Cambridge, United States
- Employees 66 as on 31 Dec, 2021
- Founders Omid Veiseh
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Sigilon
Unlock access to complete
Unlock access to complete
Funding Insights of Sigilon
Sigilon has successfully raised a total of $103.8M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $80.3 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sigilon
Sigilon has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, BlackRock and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding.
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked | |
|
Pension fund assets are managed for sustainable long-term growth.
|
Locked | Locked | Locked |
Investor details for Sigilon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sigilon
Investment portfolio details for Sigilon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sigilon
Detailed financials for Sigilon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sigilon Comparisons
Peer comparison for Sigilon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sigilon
Sigilon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Zucara Therapeutics, MBX Biosciences and Amolyt Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| Locked | Locked | Locked |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| Locked | Locked | Locked |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| Locked | Locked | Locked |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| Locked | Locked | Locked |
Immune-mediated targeted therapies for cancer are developed.
|
Detailed competitors of Sigilon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sigilon
Complete news archive for Sigilon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sigilon
Sigilon was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Sigilon is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Sigilon is a funded company, having raised a total of $103.8M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Sigilon is 66.
Sigilon was founded in 2015 in Cambridge, United States, within the biotechnology sector. Therapeutics targeting chronic diseases are created using cell engineering and proprietary biocompatible materials. The Shielded Living Therapeutics (SLTx) platform is employed to address various conditions. A pipeline is maintained for rare blood disorders, lysosomal diseases, and endocrine diseases, with operations focused on therapeutic development.
Sigilon's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
Sigilon has 5 investors. Key investors include Lilly, BlackRock, Flagship Pioneering, CPP Investments, and Longevity Vision Holding.